Brief: China Resources Pharmaceutical Posts FY Net Profit Attributable RMB444.7 Mln For KPC Pharmaceuticals
21/03/2024 22:50
March 22 (Reuters) - China Resources Pharmaceutical
Group Ltd 3320.HK :
* FY NET PROFIT ATTRIBUTABLE RMB444.7 MILLION VERSUS VERSUS
RMB383.2 MILLION FOR KPC PHARMACEUTICALS
* FY REVENUE RMB7.70 BILLION VERSUS RMB8.28 BILLION FOR KPC
PHARMACEUTICALS
* KPC PROPOSED CASH DIVIDEND OF RMB2 FOR EVERY 10 SHARES SET
FOR
APPROVAL AT 2023 AGM
Further company coverage: 3320.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Resources Pharmaceutical
See all newsBrief: China Resources Pharmaceutical Group Declares Interim Dividend Of RMB0.087 Per Share
Brief: China Resources Pharmaceutical Says Tasly Pharmaceutical Posts HY Net Profit Attributable Of RMB 892.7 MLN
Brief: China Resources Pharmaceutical Group Says HY Revenue RMB 1.93 Billion For CR Jiangzhong
Brief: China Resources Pharmaceutical Group Posts HY Revenue RMB 1.64 Billion, Down 50.97% For KPC Pharmaceuticals
Brief: China Resources Pharmaceutical Says CR Boya Bio-Pharmaceutical Posts Quarterly Unaudited Revenue RMB 321.1 Million, Net Profit RMB 30.0 Million